New Approvals in Low- and Intermediate-Risk Myelodysplastic Syndromes
Journal Title:
American Society of Clinical Oncology Educational Book
Original Publication Date:
May 2025
Bone Marrow Disease(s):
Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: Phase 2 ESCALATE trial
Key Points
Eltrombopag combined with IST demonstrated a trend towards a favorable ORR in pediatric patients with r/r SAA.
The PK profile for eltrombopag was similar to that observed in patients with ITP, and no unexpected safety signals were observed in children
Donor regulatory T-cell therapy to prevent graft-versus-host disease
Key Points
Treg-engineered donor graft prevents acute and chronic GVHD.
Patients treated with Treg-engineered graft who develop GVHD respond to primary corticosteroid therapy at a high rate.
Taking Charge of My Care and Advocacy Following a Cancer Diagnosis
After a long battle with illness and seeking many specialists, I emphasize the need to self-advocate for ongoing care following my cancer diagnosis.
Prognostic Significance of Monocytic-like Phenotype in AML patients treated with Venetoclax and Azacytidine
Key Points
The impact of ABO compatibility on allogeneic hematopoietic cell transplantation outcomes: a contemporary and comprehensive study from the transplant complications working party of the EBMT
Abstract
Support is Growing to Restore Funding to CDMRP and BMFRP Research Programs
Thanks to the efforts of our AAMDSIF bone marrow failure community and coalition partners, a bipartisan group of 105 U.S.
AAMDSIF Calls for Restoration of Bone Marrow Failure Research Funding
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients
Pre-transplant inflammation and its associations with acute GvHD and mortality in pediatric allogeneic hematopoietic stem cell transplantation patients
Abstract